Eli Lilly could face risk in Zyprexa case
A patent protecting Zyprexa, a schizophrenia treatment that is Eli Lilly's biggest selling drug, is under greater than expected risk from a court challenge by a generic competitor, according to new
A patent protecting Zyprexa, a schizophrenia treatment that is Eli Lilly's biggest selling drug, is under greater than expected risk from a court challenge by a generic competitor, according to new